Potential savings of $1,500/month compared with other generic versions
CivicaScript, LLC, a nonprofit company dedicated to bringing low-cost generic medicines to U.S. patients, announced the availability of its generic capecitabine. Capecitabine is a nucleoside metabolic inhibitor indicated for certain types of colorectal, breast, gastric, esophageal, gastroesophageal junction or pancreatic cancer.
Health Technology Insights: TOBY Completes Nashville Entrepreneur Center’s Project Healthcare Accelerator
CivicaScript will offer capecitabine 500 mg film-coated tablets for sale to pharmacies for $63 per bottle of 120 tablets. CivicaScript recommends that pharmacies charge patients no more than $84 per bottle (CivicaScript’s maximum retail price, or MaxRP policy). CivicaScript will offer the 150 mg and 500 mg strengths of capecitabine tablets for sale.
CivicaScript’s MaxRP policy provides a way for healthcare providers, caregivers, patients and others to compare prices; consumers can confirm they are being charged no more than the MaxRP by scanning the QR code featured on the CivicaScript product label.
CivicaScript’s MaxRP for capecitabine 500 mg tablets is about $1,500 per month less than the average claim cost for prescriptions filled at traditional PBM-affiliated pharmacies. It could significantly reduce patients’ out-of-pocket costs during the deductible phase of their health insurance, in which they pay full price for their medicines. Savings also could be substantial for patients with co-insurance, which charges them a percentage of their medicines’ price.
Health Technology Insights: GHX Deploys New Wave of AI Capabilities to Advance the Healthcare Supply Chain
“The momentum we’re creating with our transparent business model is proving to be both successful and sustainable,” said CivicaScript President Brent J. Eberle. “We’re aligning all stakeholders to prioritize the lowest sustainable cost, which means lower prices for patients and cost savings throughout the system.”
A recent report in The New England Journal of Medicine Catalyst showed that CivicaScript’s first product, abiraterone, saved consumers 64% and payers 92% when they switched from other versions of the same drug.
CivicaScript partners with manufacturers to produce low-cost generic medicines, then works with payers and pharmacies across the country to pass along the cost savings to patients. CivicaScript’s business model focuses on transparency and collaboration throughout the value chain from manufacturing through dispensing — with every stakeholder along the way knowing the price of the medicine and driving savings through to the patient.
Capecitabine was chosen by CivicaScript members as a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product.
While many generic medicines cost less than brand-name drugs, some high-cost generics are more expensive than they need to be. Numerous studies confirm that medication costs can dictate whether patients ration their prescriptions or even fill them in the first place.
Health Technology Insights: Ultrasound AI, MedLatam Partner to Expand Prenatal Diagnostics
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
